Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FT538 + daratumumab
- Development stage
- Unknown
- Lead developer
- Fate Therapeutics
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous, Subcutaneous
01
Overview
FT538 + daratumumab is a **combination therapy** comprising FT538, an off-the-shelf induced pluripotent stem cell (iPSC)-derived, multi-engineered natural killer (NK) cell product, paired with daratumumab, a CD38-targeting monoclonal antibody. FT538 is genetically modified to lack CD38 (to avoid daratumumab-induced NK cell fratricide), expresses a high-affinity non-cleavable CD16 Fc receptor for enhanced antibody-dependent cellular cytotoxicity (ADCC), and an IL-15/IL-15 receptor fusion protein for improved persistence. Daratumumab specifically targets CD38 on malignant myeloma cells, inducing cell death through ADCC, complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP). Together, this combination is designed to maximize tumor cell killing in diseases like multiple myeloma and potentially acute myeloid leukemia, by enabling daratumumab-driven NK cell cytotoxicity while preserving NK cell survival, persistence, and function[1][3][4][7].
- Other names
- FT538 + DarzalexFT538 + anti-CD38 monoclonal antibody
02
Targets
IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)CD38 (Cluster of Differentiation 38)
Beyond the preview
Go deeper on FT538 + daratumumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FT538 + daratumumab.